A Phase I Study of iPS Cell Generation From Patients With COPD

Not Applicable

Completed

• Conditions: Thoracic Diseases; Neoplasms, Lung; Carcinoma, Non-Small-Cell Lung; Pulmonary Emphysema; Neoplasms, Pulmonary; Pulmonary Cancer; Carcinoma, Small Cell; Cancer of the Lung; Lung Cancer; Lung Diseases, Obstructive
• Interventions: Other: Skin Biopsy

• Registration Number: NCT01860898
• Lead Sponsor: Mayo Clinic

Brief Summary

As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, the investigators will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-09
• Study First Submitted: 2013-05-21
• Study First Submitted QC: 2013-05-22
• Study First Posted: 2013-05-23
• Primary Completion: 2014-10-28
• Study Completion: 2014-10-28
• Status Verified: 2022-09
• Last Update Submitted: 2022-09-27
• Last Update Posted: 2022-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

• Undergoing Thoracic Surgery at the Mayo Clinic Rochester
• Presence of a Thoracic Disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Skin Biopsy	Skin Biopsy	-

Primary Outcome Measures

Name	Time	Method
Feasibility	1 year	As part of the long-term goal of successfully implementing tissue regeneration strategies in an individualized manner for patients with thoracic diseases including, but not limited to: cystic fibrosis, pulmonary fibrosis and pulmonary hypertension, we will assess the feasibility of collecting skin biopsies from patients undergoing surgery for thoracic disease, culturing skin fibroblasts from the biopsy, and reprogramming these skin fibroblasts into induced pluripotent cells. Markers of induced pluripotent phenotype will be utilized to assess successful reprogramming.

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States